Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

"Declaration of Competing Interest Dr. F. Tazza has nothing to disclose. Dr. C. Lapucci has nothing to disclose. Dr. M. Cellerino has nothing to disclose. Dr. G. Boffa has nothing to disclose. Dr. G. Novi has nothing to disclose. Ms. I. Poire has nothing to disclose. Dr. E. Mancuso has nothing to disclose. Dr. N. Bruschi has nothing to disclose. Dr. E. Sbragia has nothing to disclose. Dr. A. Laroni received grants from Italian MS Society, Italian Ministry of Healthy, Italian Ministry for University; fees for consultation from Biogen, Novartis, Merck, Roche. Dr. E Capello received honoraria for consultation from Merck, Novartis and Almirall. Dr. M. Inglese received grants NIH, NMSS, FISM; received fees for consultation from Roche, Genzyme, Merck, Biogen and Novartis."

"Funding This study did not receive any funding support."